Even with several metric reports available, Michelle Petri, MD, MPH, explains that measuring the outcomes of systemic lupus erythematosus (SLE) is difficult.
Dr Petri explains that measuring outcomes is challenging because multiple organ sites are involved; and because the disease presents in many different ways, healthcare professionals often utilize available indexes as research tools.
Instead of referring to a single guideline when making treatment decisions, healthcare professionals assess these metrics in combination.
Additionally, a correct diagnosis often does not occur until after the disease has become full-fledged. Generally, a patient first seeks the opinion of his or her primary care physician. Often, by the time a correct diagnosis is made with a specialist such as a rheumatologist, the disease has caused permanent damage. Therefore, Dr Petri believes it is necessary to address this issue by enforcing rapid referral to academic rheumatology practices.
Furthermore, Maria Lopes, MD, MS, explains that another challenge to the treatment of SLE, even with the availability of national guidelines, is the overall cost of treatment. Dr Petri agrees and explains that the approval of Benlysta (belimumab), the first biologic approved for lupus, is very expensive due to results of clinical trials that revealed only a 10% difference in outcomes between the group treated with Benlysta and the standard-of-care group.
American Advocacy and Action for Minority Health in 2025
April 4th 2025Accessing equitable health care is an ongoing struggle in the US for minority communities due to historical pretexts with new setbacks surfacing as recent administrative changes emerge, highlighting the urgent need for continued advocacy during National Minority Health Month.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Robert F. Kennedy Jr Faces Senate Inquiry Over Deep Cuts to HHS Impacting FDA, CDC, NIH, CMS
April 2nd 2025A bipartisan letter from lawmakers questions the legality of Robert F. Kennedy Jr's HHS changes and the lack of clear communication regarding their potential impact on American health.
Read More